Nuvectis Pharma, Inc.NVCTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +11.92% | +20.40% | +26.42% | +31.85% | +11.88% |
| Weighted Average Shares Diluted Growth | +11.92% | +20.40% | +26.42% | +31.85% | +11.88% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -3.01% | +52.93% | +47.60% | +105.62% | +70.41% |
| Book Value per Share Growth | -28.87% | +24.12% | +6.53% | +65.68% | +69.43% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +5.42% | +38.35% | +22.77% | +104.82% | +13.12% |
| SG&A Expenses Growth | -24.91% | +8.76% | +75.41% | +31.17% | +29.60% |